This site uses cookies to bring you the best experience. Find out more
Skip to main content

INVESTMENT CASE

 

SIGNIFICANT MARKET OPPORTUNITIES

High demand for sustainable products that can compete with conventional products on ease-of-use, efficacy, safety, cost and reliability.

  • Ongoing pressure on the conventional pesticides market, which is subject to increased scrutiny and regulatory pressures contributing to significant disruption.

  • Increasing time and cost of bringing new chemical products to market:
    12 years and around $300 million.

  • Significantly lower costs of bringing biopesticides to market – around $25-50 million.

  • Major product withdrawals across all segments of the conventional crop protection industry are having a significant impact on growers leaving them with lower yields and declining productivity.

UNIQUE TECHNOLOGY

Sustaine encapsulation technology is free from plastics/polymers and facilitates phased release over multiple hydration events.

  • Ownership of the patents behind the Sustaine encapsulation technology.

  • Proven efficacy with strong commercial validation by farmers and our partners.

  • Scope to exploit the core technologies beyond existing markets and products.

  • Eden’s products serve as sustainable alternatives to conventional chemicals without limitations such as residue limits, pest resistance, pre-harvest intervals, long field re-entry periods or increasing restrictions on use.

  • Residue-free crops command a higher value and have a significant commercial advantage in the valuable export markets.

CLEAR COMMERCIAL PROGRESS

Product sales continue to progress well with expansion into new markets.

  • Solid commercial pipeline.

  • Regulatory clearance for product sales across multiple countries with applications pending in 29 new countries.

  • Commercial and collaborative relationships with strong industry partners.

  • Significant investment in commercialisation by key partners.

  • Key crops expected to grow from one to more than ten in the next three years.

  • Sales on two continents today – expected to expand to six in the coming years.

SKILLED AND EXPERIENCED PROFESSIONALS

Building on a core team with significant industrial experience.

  • Strong Board and management team.

  • Lykele van der Broek appointed as Non-Executive Director and Chairman – former Board member and COO of Bayer CropScience.

  • Wealth of experience in the agriculture, consumer products and animal health sectors globally.

  • Outsourcing of some functions to maintain a flexible, low overheard base.

TRAJECTORY OF FINANCIAL GROWTH

Continuous development of sales territories and distributor relationships.

  • Increased revenue generation from product sales.

  • Significant investment by key partners.

  • Robust balance sheet and cash position.

 


Revenue
 

£2.8m

(2017: £1.9m)
 

Upfront and
milestone payments

£1.2m

(2017: £1.1m)
 

Operating profit*
 

£0.02m

(2017: loss £0.6m)
 


Product sales
increased 112%

£1.6m

(2017: £0.8m)
 

Operating loss
 

£0.5m

(2017: £0.6m)
 

Net cash
 

£2.5m

(2017: £3.7m)
 


 

* before non-cash share based payment charge, amortisation and royalties refund

 


£14m

invested in IP
and registration


 

11

countries have granted product authorisation
 

5

continents currently
with ongoing trials